SEARCH:   Advanced

Blood, 1 April 2005, Vol. 105, No. 7, pp. 2991-2994. Prepublished online as a Blood First Edition Paper on December 16, 2004; DOI 10.1182/blood-2004-09-3715. This Article Full Text (PDF) All Versions of this Article: 2004-09-3715v1 105/7/2991    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Flierman, R. Articles by van Laar, J. M Search for Related Content PubMed PubMed Citation Articles by Flierman, R. Articles by van Laar, J. M Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted September 24, 2004 Accepted December 9, 2004 Control of systemic B cell-mediated autoimmune disease by nonmyeloablative conditioning and MHC-mismatched allogeneic bone marrow transplantation Roelof Flierman*, Hendrik J Witteveen, Ellen I van der Voort, Tom W Huizinga, Rene R de Vries, Willem E Fibbe, Rene E Toes, and Jacob M van Laar Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands * Corresponding author; email: r.flierman{at}lumc.nl. Systemic autoimmune diseases (AID) can be controlled with conventional therapies in the majority of patients. However, relapses are common, leading to progressive disability and premature mortality. Nonmyeloablative conditioning and allogeneic bone marrow transplantation (BMT) could be an effective treatment for severe AID, because of mild toxicity of the conditioning and potential benefits of donor chimerism. We examined the effects of this treatment in experimental autoimmune arthritis. Our results demonstrate the induction of complete donor chimerism and significant suppression of disease activity. No clinical graft-versus-host disease (GVHD) was observed. The beneficial effects were most likely caused by the elimination of plasma cells producing pathogenic autoantibodies as these antibodies disappeared rapidly after BMT. Although this type of treatment was able to treat organ-specific T cell-mediated AID, the present study provides convincing evidence that nonmyeloablative conditioning and allogeneic BMT can effectively treat severe B cell-mediated AID with a systemic inflammatory component. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: From animals to clinic: nonmyeloablative conditioning and allogeneic bone marrow transplantation in autoimmune disease Richard K. Burt Blood 2005 105: 2623-2624. [Full Text] [PDF] This article has been cited by other articles: R. Flierman, G. Westerhuis, M. Hameetman, L. M. van Duivenvoorde, T. van Hall, J. M. van Laar, W. E. Fibbe, and R. E. M. Toes Targeting host B-cell immune responses by persistent donor NK-cell alloreactivity following nonmyeloablative allogeneic stem cell transplantation Blood, June 15, 2007; 109(12): 5524 - 5525. [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020